Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.

AD Zelenetz; W Jurczak; V Ribrag; K Linton; GP Collins; J Lopez-Jimenez; N Reddy; A Mengarelli; TJ Phillips; G Musuraca; O Sheehy; J Li; W Xu; MM Azoulay; R Ghalie; PL Zinzani

Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.

AD Zelenetz, W Jurczak, V Ribrag, K Linton, GP Collins, J Lopez-Jimenez, N Reddy, A Mengarelli, TJ Phillips, G Musuraca, O Sheehy, J Li, W Xu, MM Azoulay, R Ghalie, PL Zinzani

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	40
Issue number	16
Publication status	Published - 1 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Zelenetz, AD., Jurczak, W., Ribrag, V., Linton, K., Collins, GP., Lopez-Jimenez, J., Reddy, N., Mengarelli, A., Phillips, TJ., Musuraca, G., Sheehy, O., Li, J., Xu, W., Azoulay, MM., Ghalie, R., & Zinzani, PL. (2022). Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL. Journal of Clinical Oncology, 40(16).

@article{ff8be34ae05243938cc6d96bc99ebaff,

title = "Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.",

author = "AD Zelenetz and W Jurczak and V Ribrag and K Linton and GP Collins and J Lopez-Jimenez and N Reddy and A Mengarelli and TJ Phillips and G Musuraca and O Sheehy and J Li and W Xu and MM Azoulay and R Ghalie and PL Zinzani",

year = "2022",

month = jun,

day = "1",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

}

Zelenetz, AD, Jurczak, W, Ribrag, V, Linton, K, Collins, GP, Lopez-Jimenez, J, Reddy, N, Mengarelli, A, Phillips, TJ, Musuraca, G, Sheehy, O, Li, J, Xu, W, Azoulay, MM, Ghalie, R & Zinzani, PL 2022, 'Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.', Journal of Clinical Oncology, vol. 40, no. 16.

Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL. / Zelenetz, AD; Jurczak, W; Ribrag, V et al.
In: Journal of Clinical Oncology, Vol. 40, No. 16, 01.06.2022.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL)

T2 - Primary analysis of the global phase 2 study TIDAL.

AU - Zelenetz, AD

AU - Jurczak, W

AU - Ribrag, V

AU - Linton, K

AU - Collins, GP

AU - Lopez-Jimenez, J

AU - Reddy, N

AU - Mengarelli, A

AU - Phillips, TJ

AU - Musuraca, G

AU - Sheehy, O

AU - Li, J

AU - Xu, W

AU - Azoulay, MM

AU - Ghalie, R

AU - Zinzani, PL

PY - 2022/6/1

Y1 - 2022/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000863680301972&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL.

UN SDGs

Other files and links

Cite this